Background: Hereditary transthyretin amyloidosis (ATTRv) is a treatable multisystem disorder with prevalent peripheral nervous system impairment. Besides neurophysiological measures, there are few markers to monitor disease progression. Neurofilament light chain (NfL) has recently been considered a sensitive biomarker for neuroaxonal damage in this setting. Objective: To evaluate NfL levels in a cohort of ATTRv patients and pre-symptomatic carriers and correlate the serum concentrations with other markers of disease severity. Methods: We analysed NfL serum from 17 ATTRv patients or carriers and 26 controls. An exhaustive clinical and instrumental evaluation was performed in all patients. Results: NfL levels were significantly higher in ATTRv cases when compared with controls. A significant correlation was found between NfL values and NIS scale, Sudoscan values from feet, interventricular septum thickness, and Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) questionnaire. Conclusion: We confirm that NfL is a reliable and promising biomarker to evaluate the ATTRv severity and monitor its progression.
Luigetti, M., Di Paolantonio, A., Guglielmino, V., Romano, A., Rossi, S., Sabino, A., Servidei, S., Sabatelli, M., Primiano, G., Neurofilament light chain as a disease severity biomarker in ATTRv: data from a single-centre experience, <<NEUROLOGICAL SCIENCES>>, 2022; 43 (4): 2845-2848. [doi:10.1007/s10072-021-05850-7] [http://hdl.handle.net/10807/205626]
Neurofilament light chain as a disease severity biomarker in ATTRv: data from a single-centre experience
Luigetti, M.;Di Paolantonio, A.;Guglielmino, V.;Romano, A.;Rossi, S.;Servidei, S.Ultimo
;Sabatelli, M.;Primiano, G.
2022
Abstract
Background: Hereditary transthyretin amyloidosis (ATTRv) is a treatable multisystem disorder with prevalent peripheral nervous system impairment. Besides neurophysiological measures, there are few markers to monitor disease progression. Neurofilament light chain (NfL) has recently been considered a sensitive biomarker for neuroaxonal damage in this setting. Objective: To evaluate NfL levels in a cohort of ATTRv patients and pre-symptomatic carriers and correlate the serum concentrations with other markers of disease severity. Methods: We analysed NfL serum from 17 ATTRv patients or carriers and 26 controls. An exhaustive clinical and instrumental evaluation was performed in all patients. Results: NfL levels were significantly higher in ATTRv cases when compared with controls. A significant correlation was found between NfL values and NIS scale, Sudoscan values from feet, interventricular septum thickness, and Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) questionnaire. Conclusion: We confirm that NfL is a reliable and promising biomarker to evaluate the ATTRv severity and monitor its progression.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
